Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 589-595

  Moon, Eunyi ^a   Lee, Richard ^a   Near, Richard ^a   Weintraub, Lewis ^a   Wolda, Sharon ^c   Lerner, Adam ^a,b  

^a BOSTON MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAMIDE; CYCLIC AMP; FORSKOLIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE 7A; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CYCLIC AMP; HUMANS; ISOENZYMES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PHOSPHODIESTERASE INHIBITORS; PROTEIN ISOFORMS; QUINOLONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROLIPRAM; TIME FACTORS; UP-REGULATION;

EID: 0036188156     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Theophylline, a new inducer of apoptosis in B-CLL: Role of cyclic nucleotides
2. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells
3. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia
4. Therapeutic efficacy of theophylline in chronic lymphocytic leukemia
5. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants
6. Challenge of human Jurkat T cells with the adenylate cyclase activator forskolin elicits major changes in cAMP PDE expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down regulating a novel PDE4A splice variant
7. Cyclic AMP phosphodiesterases in human lymphocytes
8. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation
9. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2 and 4D3 in Jurkat T cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor antagonists
10. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase - Basic and potential clinical applications
11. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions
12. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia
13. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies
14. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human GMP-inhibited cyclic nucleotide phosphodiesterase family
15. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs
16. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae
17. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
18. Phosphodiesterases and cyclic nucleotide signaling in endocrine cells
19. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module
20. The short-term activation of a rolipram sensitive, cAMP-specific phosphodiesterase by thyroid stimulating hormone in thyroid FRTL-5 cells is mediated by a CAMP-dependent phosphorylation
21. The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579
22. Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice
23. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D
24. Identification and characterization of the type 4A cyclic-AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in the cerebellum
25. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells
26. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4
27. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th-1-mediated autoimmune diseases
28. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors
29. Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis
30. Characterization of the phosphodiesterase (PDE) pattern of in-vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function
31. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
32. Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: A potential novel approach to preventing allograft rejection?
33. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4
34. Evidence that cAMP phosphodiesterase inhibitors suppress interleukin 2 release from murine splenocytes by interacting with a "low affinity" phosphodiesterase 4 conformer
35. Inhibition of platelet-derived growth factor-induced mitogenesis by phosphodiesterase 3 inhibitors: Role of protein kinase A in vascular smooth muscle mitogenesis
36. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes
37. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase II and IV inhibitor, in patients with asthma
38. Phosphodiesterase profiles of highly purified human peripheral blood leucocyte populations from normal and atopic individuals: A comparative study
39. Enzymatic and functional aspects of dual selective PDE3/4 inhibitors
40. A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial
41. Therapeutic use of a selective cAMP phosphodiesterase inhibitor (rolipram) in Parkinson’s disease
42. Results of a Phase II study of the antidepressant effect of rolipram
43. Is phosphodiesterase inhibition a new mechanism of antidepressant action?
44. Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine
45. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease